PROK - Total Utang marang Modal ProKidney Pharma

Logo perusahaan publik ProKidney Corp. (PROK)

ProKidney Corp. (PROK) resilience is based on automated bioreactors that eliminate manual labor errors. The debt-to-equity ratio trend confirms the startup's financial structure, where 0.00 reflects the metric's baseline level. Investors are accounting for the company's volatile image due to anticipation of trial data, as well as the implementation of zero-waste synthesis technologies to comply with environmental standards in laboratories.

PROK: Total Utang marang Modal ProKidney 28.04.2023 - 29.10.2026

Rincian analitis perusahaan ProKidney Corp.

- rega lan prakiraan konsensus rega:
Bagan rega ProKidney|PROK - Bagan tingkat prakiraan
- statistik kapitalisasi pasar:
Kapitalisasi pasar ProKidney|PROK - Nilai Dipunlarasaken Utang lan Kas
- indikator kapitalisasi buku:
Nilai Buku saben Saham ProKidney|PROK - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku prokidney.com|PROK - Nilai Agregat Aset
- indikator total utang lan likuiditas perusahaan:
Utang marang Ekuitas ProKidney Corp.|PROK - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal ProKidney Corp.|PROK - Gunggung utang perusahaan|Utang marang nilai buku ProKidney|PROK - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan ProKidney
Analisis dhasar perusahaan:ProKidney
Barang utama ProKidney Pharma

Capital serves as a filter separating sustainable enterprises from speculative assets. The stability of ProKidney Corp. (PROK) is confirmed by the retention of key cell biologists due to the high scientific significance of its developments. The ratio of total liabilities to equity determines the degree of financial leverage. By analyzing the dynamics of the company's financial dependence, an investor assesses the risk of business degradation as indebtedness rises. A decrease in this coefficient signals strengthening solvency and long-term sustainability.

Analisis pesaing ProKidney Corp.

Utang marang Ekuitas Travere Therapeutics, Inc.|Ardelyx Inc - Utang Agregat marang Ekuitas|Total Utang marang Modal AKBA|TVRD (Cara Corp) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal DMAC (DiaMedica Therapeutics)|Total Utang marang Modal unicycive.com UNCY|RMTI - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi CVKD (Cadrenal Therapeutics Inc.)|Conduit Pharma (CDT) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas Calliditas Therapeutics AB|RNLX (Renalytix PLC) - Total Utang marang Modal|Total Utang marang Modal ZyVersa